Return to Listing

13 result(s) for Prostate

PI Name Protocol # Title
Julie Graff IRB00005254 A Phase II Study of CTLA Blockade by Ipilimumab plus Androgen Suppression Therapy in Patients with an Incomplete Response to AST Alone for Metastatic Prostate Cancer
Tomasz Beer IRB00005688 A Phase II study of MAOA inhibitor plus docetaxel in patients receiving and progressing on docetaxel therapy
Jeremy Cetnar IRB00008962 A phase 1/2 study combining ipilimumab with abiraterone acetate plus prednisone in chemotherapy- and immunotherapy-naïve patients with progressive metastatic castration-resistant prostate cancer
Tomasz Beer IRB00009204 Radiologically Guided Biopsies of Metastatic Castration Resistant Prostate Cancer to Identify Adaptive Mechanisms of Resistance
Joshi Alumkal IRB00009259 Identifying Mechanisms of Resistance to Enzalutamide (MDV3100) Treatment in Men with Castration-Resistant Prostate Cancer
Julie Graff IRB00009363 PVAMC / OHSU J: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer
Joshi Alumkal IRB00010241 Molecular Mechanisms Underlying Tumor Progression Despite Enzalutamide Treatment
Christopher Amling IRB00010252 An Open Registry to Measure the Impact of Adding Genomic Testing (Prolaris®) on the Treatment Decision Following Biopsy in Newly Diagnosed Prostate Cancer Patients by Specialists
Xin Li IRB00010345 Contrast Enhanced MRI of the Prostate
Tomasz Beer IRB00010479 A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men with Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy
Julie Graff IRB00010586 PVAMC/OHSU J: A three arm randomized, open-label Phase II study of radium-223 dichloride 50 kBq/kg versus 80 kBq/kg, and versus 50 kBq/kg in an extended dosing schedule in subjects with castration-resistant prostate cancer metastatic to the bone
Julie Graff IRB00011025 PVAMC / OHSU J: Addition of Pembrolizumab Upon Progression on Enzalutamide in men with mCRPC
Kerri Winters IRB00011765 Health & Mobility in Prostate Cancer Survivors
 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080
 

You may qualify for additional trials within our Phase 1 Program